Maria Makarova

Maria Makarova



+ 7 495 545 39 12

Send message

Additionally to participation in Team Drive Marya Maria is Chief Financial Officer at RMI Partners (venture capital investment company) and at pharmaceutical company NovaMedica.

Maria has over 15 years of experience in finance. She started her professional career at one of the "Big 4" companies, where she worked in the audit department for more than 12 years. Subsequently Maria participated in the creation and development of a large management company, where she was responsible for general operational project management of medical services and medical technology, in addition to her financial management responsibilities.

Maria Makarova holds a Bachelor’s degree in Mathematics and Finance, MBA and CPA (US Certified Public Accountant). 

In 2016 and 2017, Maria was listed in the TOP-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.

Media Center

  • 16 February 2018

    Pfizer taps BC for real-world cardiovascular research drive

    Pfizer has teamed up with BC Platforms to generate real-world evidence on cardiovascular diseases. The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.

  • 16 February 2018

    Pharma and AI: Help doctors with AI assistants but don’t try to replace them

    Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors.

  • 15 February 2018

    Pharma Looks to Change the Healthcare Cost Conversation

    Amidst the continuing clamor for government action to curb prescription drug prices, a more collaborative effort aims to broaden the debate to consider the full range of healthcare services and rates that affect spending in this area. The National Pharmaceutical Council (NPC), a pharma-funded research organization, is partnering with the independent journal Health Affairs to examine the root causes of rising healthcare outlays in the United States. This two-year program will support academic and professional research projects and commentaries to be published and disseminated online by the journal.

  • 15 February 2018

    FDA Releases Guidance on Systemic Antibacterial Drugs

    FDA published guidance on the development, analysis, and presentation of microbiology data during the development of antibacterial drugs. The agency discusses the overall microbiology development program it says is needed to support clinical development and approval of antibacterial drugs administered systemically. The guidance also addresses microbiology data collected after drug approval.

Read more